Aberdeen Group plc lowered its position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB – Free Report) by 67.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 100,878 shares of the company’s stock after selling 210,416 shares during the period. Aberdeen Group plc’s holdings in Zai Lab were worth $2,657,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of ZLAB. Nan Fung Trinity HK Ltd. boosted its stake in Zai Lab by 106.9% in the third quarter. Nan Fung Trinity HK Ltd. now owns 293,966 shares of the company’s stock worth $7,743,000 after purchasing an additional 151,883 shares in the last quarter. Seven Fleet Capital Management LP grew its holdings in shares of Zai Lab by 74.7% during the second quarter. Seven Fleet Capital Management LP now owns 136,016 shares of the company’s stock worth $2,584,000 after purchasing an additional 58,158 shares during the last quarter. Headlands Technologies LLC grew its holdings in shares of Zai Lab by 142.0% during the second quarter. Headlands Technologies LLC now owns 68,010 shares of the company’s stock worth $1,292,000 after purchasing an additional 39,901 shares during the last quarter. Alps Advisors Inc. increased its stake in shares of Zai Lab by 34.9% in the third quarter. Alps Advisors Inc. now owns 148,993 shares of the company’s stock valued at $3,924,000 after buying an additional 38,562 shares in the last quarter. Finally, WealthPlan Investment Management LLC acquired a new stake in shares of Zai Lab in the third quarter valued at $969,000. 41.65% of the stock is owned by institutional investors and hedge funds.
Zai Lab Stock Performance
ZLAB stock opened at $21.03 on Friday. The company has a 50 day moving average price of $24.36 and a 200 day moving average price of $21.40. Zai Lab Limited Unsponsored ADR has a fifty-two week low of $15.96 and a fifty-two week high of $29.02.
Zai Lab (NASDAQ:ZLAB – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.18. The firm had revenue of $108.21 million for the quarter, compared to the consensus estimate of $107.90 million. Zai Lab had a negative return on equity of 31.15% and a negative net margin of 44.91%. As a group, equities analysts predict that Zai Lab Limited Unsponsored ADR will post -2.19 EPS for the current year.
Insider Activity at Zai Lab
In other news, Director Richard Gaynor bought 1,228 shares of the stock in a transaction dated Tuesday, November 10th. The stock was bought at an average cost of $27.19 per share, with a total value of $33,389.32. Following the purchase, the director owned 81,965 shares of the company’s stock, valued at approximately $2,228,628.35. This represents a 1.52% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 4.88% of the company’s stock.
Wall Street Analyst Weigh In
A number of research analysts recently issued reports on ZLAB shares. Wall Street Zen raised Zai Lab from a “sell” rating to a “hold” rating in a report on Saturday, September 26th. Citigroup upped their price target on shares of Zai Lab from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. JPMorgan Chase & Co. increased their price objective on shares of Zai Lab from $36.00 to $37.00 and gave the stock an “overweight” rating in a report on Thursday. Cantor Fitzgerald restated an “overweight” rating on shares of Zai Lab in a research report on Tuesday, October 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Zai Lab in a research report on Tuesday, October 27th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $38.50.
Get Our Latest Stock Report on Zai Lab
Zai Lab Company Profile
Zai Lab is a biopharmaceutical company that discovers, develops and commercializes medicines for patients with serious diseases. Its research and development programs focus on oncology, immunology, neuroscience and infectious diseases. Founded in 2014 by biopharmaceutical executive Samantha Du, the company is headquartered in Shanghai and operates in China and the United States. It advances its own drug candidates and works with international partners to develop and bring therapies to market. Zai Lab’s portfolio includes medicines and development programs for cancers and other conditions, including therapies introduced through licensing and collaboration agreements.
See Also
- Five stocks we like better than Zai Lab
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Want to see what other hedge funds are holding ZLAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB – Free Report).
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.
